159 related articles for article (PubMed ID: 23248401)
21. A comparison of once-daily application of mometasone furoate 0.1% cream compared with twice-daily hydrocortisone valerate 0.2% cream in pediatric atopic dermatitis patients who failed to respond to hydrocortisone: mometasone furoate study group.
Lebwohl M
Int J Dermatol; 1999 Aug; 38(8):604-6. PubMed ID: 10487451
[No Abstract] [Full Text] [Related]
22. Effect of mometasone furoate by topical application on allergic rhinitis model in rats.
Sugimoto Y; Ishizawa K; Saitou K; Suzuki G; Tarumi T; Nakahara H; Kirino Y; Kamei C
Pharmacology; 2000 Aug; 61(2):91-5. PubMed ID: 10940782
[TBL] [Abstract][Full Text] [Related]
23. Comparison of fluticasone propionate ointment, 0.005%, and betamethasone-17,21-dipropionate ointment, 0.05%, in the treatment of psoriasis.
Roberts DT
Cutis; 1996 Feb; 57(2 Suppl):27-31. PubMed ID: 8646866
[TBL] [Abstract][Full Text] [Related]
24. Comparison of safety and efficacy of fluticasone propionate cream, 0.05%, and betamethasone valerate cream, 0.1%, in the treatment of moderate-to-severe psoriasis.
Callen J
Cutis; 1996 Feb; 57(2 Suppl):45-50. PubMed ID: 8646870
[TBL] [Abstract][Full Text] [Related]
25. Mometasone furoate 0.1%-salicylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicenter study.
Koo J; Cuffie CA; Tanner DJ; Bressinck R; Cornell RC; DeVillez RL; Edwards L; Breneman DL; Piacquadio DJ; Guzzo CA; Monroe EW
Clin Ther; 1998; 20(2):283-91. PubMed ID: 9589819
[TBL] [Abstract][Full Text] [Related]
26. Proactive maintenance therapy with a topical corticosteroid for vulvar lichen sclerosus: preliminary results of a randomized study.
Virgili A; Minghetti S; Borghi A; Corazza M
Br J Dermatol; 2013 Jun; 168(6):1316-24. PubMed ID: 23398459
[TBL] [Abstract][Full Text] [Related]
27. Systemic bioavailability of inhaled steroids: the importance of appropriate and comparable methodology.
Derendorf H; Daley-Yates PT; Pierre LN; Efthimiou J
Eur Respir J; 2001 Jan; 17(1):157-8. PubMed ID: 11307748
[No Abstract] [Full Text] [Related]
28. Topical fluticasone propionate: a review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders.
Spencer CM; Wiseman LR
BioDrugs; 1997 Apr; 7(4):318-34. PubMed ID: 18020489
[TBL] [Abstract][Full Text] [Related]
29. In vivo assessment of the atrophogenic potency of mometasone furoate, a newly developed chlorinated potent topical glucocorticoid as compared to other topical glucocorticoids old and new.
Kerscher MJ; Hart H; Korting HC; Stalleicken D
Int J Clin Pharmacol Ther; 1995 Apr; 33(4):187-9. PubMed ID: 7620686
[TBL] [Abstract][Full Text] [Related]
30. Hypothalamic-pituitary-adrenal axis effects of mometasone furoate/formoterol fumarate vs fluticasone propionate/salmeterol administered through metered-dose inhaler.
Kosoglou T; Hubbell J; Cutler DL; Johnson-Levonas AO; Xu D; Kantesaria BS; Kim K; Miller SD
Chest; 2013 Dec; 144(6):1795-1802. PubMed ID: 24077095
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of intranasal steroid spray (mometasone furoate) on treatment of patients with seasonal allergic rhinitis: comparison with oral corticosteroids.
Karaki M; Akiyama K; Mori N
Auris Nasus Larynx; 2013 Jun; 40(3):277-81. PubMed ID: 23127728
[TBL] [Abstract][Full Text] [Related]
32. Effects of topical corticosteroids on cell proliferation, cell cycle progression and apoptosis: in vitro comparison on HaCaT.
Guichard A; Humbert P; Tissot M; Muret P; Courderot-Masuyer C; Viennet C
Int J Pharm; 2015 Feb; 479(2):422-9. PubMed ID: 25556056
[TBL] [Abstract][Full Text] [Related]
33. Tachyphylaxis to topical steroid measured by histamine-induced wheal suppression.
Singh G; Singh PK
Int J Dermatol; 1986 Jun; 25(5):324-6. PubMed ID: 3721670
[TBL] [Abstract][Full Text] [Related]
34. A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis.
Guenther LC; Poulin YP; Pariser DM
Clin Ther; 2000 Oct; 22(10):1225-38. PubMed ID: 11110233
[TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of mometasone furoate cream in the treatment of steroid responsive dermatoses.
Kelly JW; Cains GD; Rallings M; Gilmore SJ
Australas J Dermatol; 1991; 32(2):85-91. PubMed ID: 1781761
[TBL] [Abstract][Full Text] [Related]
36. A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis.
Lumry WR
J Allergy Clin Immunol; 1999 Oct; 104(4 Pt 1):S150-8. PubMed ID: 10518812
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of elicitation of contact dermatitis in humans by mometasone furoate: evaluation by means of 20-MHz B scanning associated with image analysis.
Di Nardo A; Giusti G; Mantovani L; Bianchi B; Seidenari S
Dermatology; 1997; 195(2):137-41. PubMed ID: 9310720
[TBL] [Abstract][Full Text] [Related]
38. Comparison of fluticasone propionate cream, 0.05%, and hydrocortisone-17-butyrate cream, 0.1%, in the treatment of eczema.
Juhlin L
Cutis; 1996 Feb; 57(2 Suppl):51-6. PubMed ID: 8646871
[TBL] [Abstract][Full Text] [Related]
39. Comparative potency of formulations of mometasone furoate in terms of inhibition of 'PIRHR' in the forearm skin of normal human subjects measured with laser doppler velocimetry.
Kulhalli P; Chevli T; Karnik R; Sheth M; Mulgaonkar N
Indian J Dermatol Venereol Leprol; 2005; 71(3):170-4. PubMed ID: 16394405
[TBL] [Abstract][Full Text] [Related]
40. A comparison of fluticasone propionate ointment, 0.005%, and hydrocortisone-17-butyrate ointment, 0.1%, in the treatment of psoriasis.
Nurnberger FG
Cutis; 1996 Feb; 57(2 Suppl):39-44. PubMed ID: 8646868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
